Clinical Trials Browser

Recurrence × Azacitidine × 30 days × Clear all

NCT05829226 2026-05-06

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute